Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01866293 · ClinicalTrials.gov registry record · Phase 1
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
A Phase 1 study of Relapsed or Refractory Multiple Myeloma, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
- 5
- Study locations
NCT01866293 is a Phase 1 study of Relapsed or Refractory Multiple Myeloma that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 11 participants, below the 341-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 2 states.
The verdict
NCT01866293, a Phase 1 study of Relapsed or Refractory Multiple Myeloma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is an open label phase I/II trial to investigate the safety and efficacy of Cabozantinib for patients with relapsed or refractory myeloma.
Conditions Studied
Interventions
- DRUG Cabozantinib (XL184)
Study Locations (5)
New York
- Memorial Sloan Kettering Cancer Center @ Suffolk - Commack
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Cancer Center at Mercy Medical Center - Rockville Centre
- Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center - Sleepy Hollow
New Jersey
- Memoral Sloan Kettering Cancer Center - Basking Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2013-05-28 |
| Est. Completion | 2016-08-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01866293
The ClinicalTrials.gov registry entry for NCT01866293 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 341-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (97% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed or Refractory Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Cabozantinib (XL184) is the first listed.
NCT01866293 reports 5 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT01866293 about?
NCT01866293 is a clinical study titled "Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma". This study is an open label phase I/II trial to investigate the safety and efficacy of Cabozantinib for patients with relapsed or refractory myeloma.
What is the current status of trial NCT01866293?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2013-05-28. Estimated completion is 2016-08-18.
What conditions does trial NCT01866293 study?
This clinical trial studies the following conditions: Relapsed or Refractory Multiple Myeloma.
What interventions are being tested in trial NCT01866293?
The interventions under investigation include: Cabozantinib (XL184) (DRUG).
Who is sponsoring clinical trial NCT01866293?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01866293 being conducted?
This trial has 5 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed or Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
RECRUITING · Phase 1
-
A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
COMPLETED · Phase 1
-
A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.